Intranasal Drug and Vaccine Delivery Market, By Product Type (Nasal Drops and Nasal Sprays), By Application (Vaccination, Pain Management, Respiratory Disorders, and Others), By End-user (Hospitals, ...
SciSparc has identified a new way to get its cannabinoid receptor type 2 (CB2R) agonist to targets in the brain. Having run initial studies on an intravenous formulation, the Israeli biotech is now ...
Polyrizon Ltd., a biotech company based in Raanana, Israel, announced the publication of a national phase patent application by the USPTO for its innovative intranasal hydrogel technologies. These ...
A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in ...
Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The "Nasal Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal ...
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal ...
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...
In a recent study published in the Journal of Drug Delivery Science and Technology, researchers reviewed the advances and challenges in the intranasal delivery of antibiotics. Antibiotics are ...
RIGImmune has struck a deal to acquire Subintro, giving it access to novel topical delivery systems. The deal positions the biotech to advance the development of novel RNA therapies and vaccine ...
TipRanks on MSN
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier
Polyrizon Ltd. ( ($PLRZ) ) has shared an announcement. On January 5, 2026, Polyrizon Ltd. reported positive in-vitro pre-clinical results showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback